Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenstrom macroglobulinemia (WM). PATIENTS AND METHODS Sixty-three symptomatic patients with median prior therapies of two (range, one to nine the...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2021-02, Vol.39 (6), p.565-575 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 575 |
|---|---|
| container_issue | 6 |
| container_start_page | 565 |
| container_title | Journal of clinical oncology |
| container_volume | 39 |
| creator | Treon, Steven P. Meid, Kirsten Gustine, Joshua Yang, Guang Xu, Lian Liu, Xia Patterson, Christopher J. Hunter, Zachary R. Branagan, Andrew R. Laubach, Jacob P. Ghobrial, Irene M. Palomba, M. Lia Advani, Ranjana Castillo, Jorge J. |
| description | PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).
PATIENTS AND METHODS Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity.
RESULTS The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL (P < .001 for all comparisons). Responses were impacted by mutated (Mut) MYD88 and CXCR4 status. Patients with MYD88(Mut), wild-type (WT) CXCR4 showed higher major (97.2% v 68.2%; P < .0001) and very good partial (47.2% v 9.1%; P < .01) response rates and a shorter time to major response (1.8 v 4.7 months; P = .02) versus patients with MYD88(Mut)CXCR4(Mut). Conversely, four patients who had MYD88(WT) disease showed no major responses. The median 5-year progression-free survival (PFS) rate for all patients was not reached, and was 70% and 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respectively (P = .02). In patients with MYD88(WT), the median PFS was 0.4 years (P < .01 for three-way comparisons). The 5-year overall survival rate for all patients was 87%. Grade >= 3 adverse events in more than one patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Eight patients (12.7%) experienced atrial arrhythmia, and seven of the eight continued therapy with medical management.
CONCLUSION Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status. (C) 2020 by American Society of Clinical Oncology |
| doi_str_mv | 10.1200/JCO.20.00555 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_proquest_miscellaneous_2443518194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2443518194</sourcerecordid><originalsourceid>FETCH-LOGICAL-c427t-19af2f716385091f1dcab8a0d1ab28960b98788c345b9d08d1f5be726b3c2c2c3</originalsourceid><addsrcrecordid>eNqNkcFv0zAUxiMEYmVw44x8RGIpz3bcOBckVDEY6rRJdBo3y06c1sixM9vZVPHP49JRwQ35YEvv9z6_931F8RrDHBOA91-XV3MCcwDG2JNihhmpy7pm7Gkxg5qSEnP6_aR4EeMPAFxxyp4XJ5Q0FNOGz4qfK-825VqHAZ17a_1DeTMi36MLFaZknFHo0juftjrIcYeMQ992w5j8IJNpz9B10PfGT9Hu0DpomXSHrnNFuxTRrUlbdCttp11MwQ_oUrbBb6xXkzVOD0a-LJ710kb96vE-LW7OP62XX8rV1eeL5cdV2VakTiVuZE_6Gi8oZ9DgHnetVFxCh6UivFmAanjNeUsrppoOeId7pnRNFoq2JB96Wnw46I6TGnTX5vGCtGIMZpBhJ7w04t-KM1ux8feCQ539qrLA20eB4O8mHZMYTGy1tdLpvL0gVUUZ5rjZo2cHNO8aY9D98RsMYp-XyHkJAuJ3Xhl_8_doR_hPQBngB-BBK9_HNnvb6iMGAAvKaA0M9s-lSdl975Z-cim3vvv_VvoL0AC0jg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2443518194</pqid></control><display><type>article</type><title>Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Alma/SFX Local Collection</source><creator>Treon, Steven P. ; Meid, Kirsten ; Gustine, Joshua ; Yang, Guang ; Xu, Lian ; Liu, Xia ; Patterson, Christopher J. ; Hunter, Zachary R. ; Branagan, Andrew R. ; Laubach, Jacob P. ; Ghobrial, Irene M. ; Palomba, M. Lia ; Advani, Ranjana ; Castillo, Jorge J.</creator><creatorcontrib>Treon, Steven P. ; Meid, Kirsten ; Gustine, Joshua ; Yang, Guang ; Xu, Lian ; Liu, Xia ; Patterson, Christopher J. ; Hunter, Zachary R. ; Branagan, Andrew R. ; Laubach, Jacob P. ; Ghobrial, Irene M. ; Palomba, M. Lia ; Advani, Ranjana ; Castillo, Jorge J.</creatorcontrib><description>PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).
PATIENTS AND METHODS Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity.
RESULTS The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL (P < .001 for all comparisons). Responses were impacted by mutated (Mut) MYD88 and CXCR4 status. Patients with MYD88(Mut), wild-type (WT) CXCR4 showed higher major (97.2% v 68.2%; P < .0001) and very good partial (47.2% v 9.1%; P < .01) response rates and a shorter time to major response (1.8 v 4.7 months; P = .02) versus patients with MYD88(Mut)CXCR4(Mut). Conversely, four patients who had MYD88(WT) disease showed no major responses. The median 5-year progression-free survival (PFS) rate for all patients was not reached, and was 70% and 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respectively (P = .02). In patients with MYD88(WT), the median PFS was 0.4 years (P < .01 for three-way comparisons). The 5-year overall survival rate for all patients was 87%. Grade >= 3 adverse events in more than one patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Eight patients (12.7%) experienced atrial arrhythmia, and seven of the eight continued therapy with medical management.
CONCLUSION Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status. (C) 2020 by American Society of Clinical Oncology</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.20.00555</identifier><identifier>PMID: 32931398</identifier><language>eng</language><publisher>PHILADELPHIA: Lippincott Williams & Wilkins</publisher><subject>Adenine - analogs & derivatives ; Adenine - pharmacology ; Adenine - therapeutic use ; Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Humans ; Life Sciences & Biomedicine ; Male ; Middle Aged ; Oncology ; ORIGINAL REPORTS ; Piperidines - pharmacology ; Piperidines - therapeutic use ; Science & Technology ; Survival Rate ; Waldenstrom Macroglobulinemia - drug therapy ; Waldenstrom Macroglobulinemia - mortality</subject><ispartof>Journal of clinical oncology, 2021-02, Vol.39 (6), p.565-575</ispartof><rights>2020 by American Society of Clinical Oncology 2020 American Society of Clinical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>104</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000635370500006</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c427t-19af2f716385091f1dcab8a0d1ab28960b98788c345b9d08d1f5be726b3c2c2c3</citedby><cites>FETCH-LOGICAL-c427t-19af2f716385091f1dcab8a0d1ab28960b98788c345b9d08d1f5be726b3c2c2c3</cites><orcidid>0000-0002-3868-9267 ; 0000-0002-3219-2292 ; 0000-0003-3049-4200 ; 0000-0001-6393-6154 ; 0000-0002-1689-1691 ; 0000-0001-9490-7532 ; 0000-0001-7565-2052 ; 0000-0001-5099-9156 ; 0000-0001-7361-3092</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,315,782,786,887,3731,27931,27932,39265</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32931398$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Treon, Steven P.</creatorcontrib><creatorcontrib>Meid, Kirsten</creatorcontrib><creatorcontrib>Gustine, Joshua</creatorcontrib><creatorcontrib>Yang, Guang</creatorcontrib><creatorcontrib>Xu, Lian</creatorcontrib><creatorcontrib>Liu, Xia</creatorcontrib><creatorcontrib>Patterson, Christopher J.</creatorcontrib><creatorcontrib>Hunter, Zachary R.</creatorcontrib><creatorcontrib>Branagan, Andrew R.</creatorcontrib><creatorcontrib>Laubach, Jacob P.</creatorcontrib><creatorcontrib>Ghobrial, Irene M.</creatorcontrib><creatorcontrib>Palomba, M. Lia</creatorcontrib><creatorcontrib>Advani, Ranjana</creatorcontrib><creatorcontrib>Castillo, Jorge J.</creatorcontrib><title>Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia</title><title>Journal of clinical oncology</title><addtitle>J CLIN ONCOL</addtitle><addtitle>J Clin Oncol</addtitle><description>PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).
PATIENTS AND METHODS Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity.
RESULTS The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL (P < .001 for all comparisons). Responses were impacted by mutated (Mut) MYD88 and CXCR4 status. Patients with MYD88(Mut), wild-type (WT) CXCR4 showed higher major (97.2% v 68.2%; P < .0001) and very good partial (47.2% v 9.1%; P < .01) response rates and a shorter time to major response (1.8 v 4.7 months; P = .02) versus patients with MYD88(Mut)CXCR4(Mut). Conversely, four patients who had MYD88(WT) disease showed no major responses. The median 5-year progression-free survival (PFS) rate for all patients was not reached, and was 70% and 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respectively (P = .02). In patients with MYD88(WT), the median PFS was 0.4 years (P < .01 for three-way comparisons). The 5-year overall survival rate for all patients was 87%. Grade >= 3 adverse events in more than one patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Eight patients (12.7%) experienced atrial arrhythmia, and seven of the eight continued therapy with medical management.
CONCLUSION Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status. (C) 2020 by American Society of Clinical Oncology</description><subject>Adenine - analogs & derivatives</subject><subject>Adenine - pharmacology</subject><subject>Adenine - therapeutic use</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Life Sciences & Biomedicine</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Oncology</subject><subject>ORIGINAL REPORTS</subject><subject>Piperidines - pharmacology</subject><subject>Piperidines - therapeutic use</subject><subject>Science & Technology</subject><subject>Survival Rate</subject><subject>Waldenstrom Macroglobulinemia - drug therapy</subject><subject>Waldenstrom Macroglobulinemia - mortality</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><sourceid>EIF</sourceid><recordid>eNqNkcFv0zAUxiMEYmVw44x8RGIpz3bcOBckVDEY6rRJdBo3y06c1sixM9vZVPHP49JRwQ35YEvv9z6_931F8RrDHBOA91-XV3MCcwDG2JNihhmpy7pm7Gkxg5qSEnP6_aR4EeMPAFxxyp4XJ5Q0FNOGz4qfK-825VqHAZ17a_1DeTMi36MLFaZknFHo0juftjrIcYeMQ992w5j8IJNpz9B10PfGT9Hu0DpomXSHrnNFuxTRrUlbdCttp11MwQ_oUrbBb6xXkzVOD0a-LJ710kb96vE-LW7OP62XX8rV1eeL5cdV2VakTiVuZE_6Gi8oZ9DgHnetVFxCh6UivFmAanjNeUsrppoOeId7pnRNFoq2JB96Wnw46I6TGnTX5vGCtGIMZpBhJ7w04t-KM1ux8feCQ539qrLA20eB4O8mHZMYTGy1tdLpvL0gVUUZ5rjZo2cHNO8aY9D98RsMYp-XyHkJAuJ3Xhl_8_doR_hPQBngB-BBK9_HNnvb6iMGAAvKaA0M9s-lSdl975Z-cim3vvv_VvoL0AC0jg</recordid><startdate>20210220</startdate><enddate>20210220</enddate><creator>Treon, Steven P.</creator><creator>Meid, Kirsten</creator><creator>Gustine, Joshua</creator><creator>Yang, Guang</creator><creator>Xu, Lian</creator><creator>Liu, Xia</creator><creator>Patterson, Christopher J.</creator><creator>Hunter, Zachary R.</creator><creator>Branagan, Andrew R.</creator><creator>Laubach, Jacob P.</creator><creator>Ghobrial, Irene M.</creator><creator>Palomba, M. Lia</creator><creator>Advani, Ranjana</creator><creator>Castillo, Jorge J.</creator><general>Lippincott Williams & Wilkins</general><general>American Society of Clinical Oncology</general><scope>95M</scope><scope>AFTVD</scope><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3868-9267</orcidid><orcidid>https://orcid.org/0000-0002-3219-2292</orcidid><orcidid>https://orcid.org/0000-0003-3049-4200</orcidid><orcidid>https://orcid.org/0000-0001-6393-6154</orcidid><orcidid>https://orcid.org/0000-0002-1689-1691</orcidid><orcidid>https://orcid.org/0000-0001-9490-7532</orcidid><orcidid>https://orcid.org/0000-0001-7565-2052</orcidid><orcidid>https://orcid.org/0000-0001-5099-9156</orcidid><orcidid>https://orcid.org/0000-0001-7361-3092</orcidid></search><sort><creationdate>20210220</creationdate><title>Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia</title><author>Treon, Steven P. ; Meid, Kirsten ; Gustine, Joshua ; Yang, Guang ; Xu, Lian ; Liu, Xia ; Patterson, Christopher J. ; Hunter, Zachary R. ; Branagan, Andrew R. ; Laubach, Jacob P. ; Ghobrial, Irene M. ; Palomba, M. Lia ; Advani, Ranjana ; Castillo, Jorge J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c427t-19af2f716385091f1dcab8a0d1ab28960b98788c345b9d08d1f5be726b3c2c2c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Adenine - analogs & derivatives</topic><topic>Adenine - pharmacology</topic><topic>Adenine - therapeutic use</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Life Sciences & Biomedicine</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Oncology</topic><topic>ORIGINAL REPORTS</topic><topic>Piperidines - pharmacology</topic><topic>Piperidines - therapeutic use</topic><topic>Science & Technology</topic><topic>Survival Rate</topic><topic>Waldenstrom Macroglobulinemia - drug therapy</topic><topic>Waldenstrom Macroglobulinemia - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Treon, Steven P.</creatorcontrib><creatorcontrib>Meid, Kirsten</creatorcontrib><creatorcontrib>Gustine, Joshua</creatorcontrib><creatorcontrib>Yang, Guang</creatorcontrib><creatorcontrib>Xu, Lian</creatorcontrib><creatorcontrib>Liu, Xia</creatorcontrib><creatorcontrib>Patterson, Christopher J.</creatorcontrib><creatorcontrib>Hunter, Zachary R.</creatorcontrib><creatorcontrib>Branagan, Andrew R.</creatorcontrib><creatorcontrib>Laubach, Jacob P.</creatorcontrib><creatorcontrib>Ghobrial, Irene M.</creatorcontrib><creatorcontrib>Palomba, M. Lia</creatorcontrib><creatorcontrib>Advani, Ranjana</creatorcontrib><creatorcontrib>Castillo, Jorge J.</creatorcontrib><collection>Conference Proceedings Citation Index - Science (CPCI-S)</collection><collection>Conference Proceedings Citation Index - Science (CPCI-S) 2021</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Treon, Steven P.</au><au>Meid, Kirsten</au><au>Gustine, Joshua</au><au>Yang, Guang</au><au>Xu, Lian</au><au>Liu, Xia</au><au>Patterson, Christopher J.</au><au>Hunter, Zachary R.</au><au>Branagan, Andrew R.</au><au>Laubach, Jacob P.</au><au>Ghobrial, Irene M.</au><au>Palomba, M. Lia</au><au>Advani, Ranjana</au><au>Castillo, Jorge J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia</atitle><jtitle>Journal of clinical oncology</jtitle><stitle>J CLIN ONCOL</stitle><addtitle>J Clin Oncol</addtitle><date>2021-02-20</date><risdate>2021</risdate><volume>39</volume><issue>6</issue><spage>565</spage><epage>575</epage><pages>565-575</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>PURPOSE We report the long-term findings and final analysis of a pivotal multicenter trial of ibrutinib monotherapy in previously treated patients with Waldenstrom macroglobulinemia (WM).
PATIENTS AND METHODS Sixty-three symptomatic patients with median prior therapies of two (range, one to nine therapies), of whom 40% were refractory to their previous therapy, received ibrutinib at 420 mg/d. Dose reduction was permitted for toxicity.
RESULTS The median follow-up was 59 months, and overall and major response rates were 90.5% and 79.4%, respectively. At best response, median serum immunoglobulin M declined from 3,520 to 821 mg/dL, bone marrow disease involvement declined from 60% to 20%, and hemoglobin rose from 10.3 to 14.2 g/dL (P < .001 for all comparisons). Responses were impacted by mutated (Mut) MYD88 and CXCR4 status. Patients with MYD88(Mut), wild-type (WT) CXCR4 showed higher major (97.2% v 68.2%; P < .0001) and very good partial (47.2% v 9.1%; P < .01) response rates and a shorter time to major response (1.8 v 4.7 months; P = .02) versus patients with MYD88(Mut)CXCR4(Mut). Conversely, four patients who had MYD88(WT) disease showed no major responses. The median 5-year progression-free survival (PFS) rate for all patients was not reached, and was 70% and 38% for those with MYD88(Mut)CXCR4(WT) and MYD88(Mut)CXCR4(Mut) WM, respectively (P = .02). In patients with MYD88(WT), the median PFS was 0.4 years (P < .01 for three-way comparisons). The 5-year overall survival rate for all patients was 87%. Grade >= 3 adverse events in more than one patient at least possibly related included neutropenia (15.9%), thrombocytopenia (11.1%), and pneumonia (3.2%). Eight patients (12.7%) experienced atrial arrhythmia, and seven of the eight continued therapy with medical management.
CONCLUSION Ibrutinib is highly active and produces long-term disease control in previously treated patients with WM. Treatment is tolerable. Response depth, time to major response, and PFS are impacted by MYD88 and CXCR4 mutation status. (C) 2020 by American Society of Clinical Oncology</abstract><cop>PHILADELPHIA</cop><pub>Lippincott Williams & Wilkins</pub><pmid>32931398</pmid><doi>10.1200/JCO.20.00555</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0002-3868-9267</orcidid><orcidid>https://orcid.org/0000-0002-3219-2292</orcidid><orcidid>https://orcid.org/0000-0003-3049-4200</orcidid><orcidid>https://orcid.org/0000-0001-6393-6154</orcidid><orcidid>https://orcid.org/0000-0002-1689-1691</orcidid><orcidid>https://orcid.org/0000-0001-9490-7532</orcidid><orcidid>https://orcid.org/0000-0001-7565-2052</orcidid><orcidid>https://orcid.org/0000-0001-5099-9156</orcidid><orcidid>https://orcid.org/0000-0001-7361-3092</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2021-02, Vol.39 (6), p.565-575 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2443518194 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Alma/SFX Local Collection |
| subjects | Adenine - analogs & derivatives Adenine - pharmacology Adenine - therapeutic use Adult Aged Aged, 80 and over Female Follow-Up Studies Humans Life Sciences & Biomedicine Male Middle Aged Oncology ORIGINAL REPORTS Piperidines - pharmacology Piperidines - therapeutic use Science & Technology Survival Rate Waldenstrom Macroglobulinemia - drug therapy Waldenstrom Macroglobulinemia - mortality |
| title | Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T00%3A15%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long-Term%20Follow-Up%20of%20Ibrutinib%20Monotherapy%20in%20Symptomatic,%20Previously%20Treated%20Patients%20With%20Waldenstrom%20Macroglobulinemia&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Treon,%20Steven%20P.&rft.date=2021-02-20&rft.volume=39&rft.issue=6&rft.spage=565&rft.epage=575&rft.pages=565-575&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.20.00555&rft_dat=%3Cproquest_webof%3E2443518194%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2443518194&rft_id=info:pmid/32931398&rfr_iscdi=true |